Concepts (221)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diagnostic Imaging | 11 | 2023 | 1177 | 1.190 |
Why?
|
| Pelvic Neoplasms | 4 | 2019 | 203 | 0.900 |
Why?
|
| Peritoneal Neoplasms | 5 | 2021 | 852 | 0.890 |
Why?
|
| Tomography, X-Ray Computed | 23 | 2020 | 7788 | 0.750 |
Why?
|
| Mesentery | 4 | 2021 | 74 | 0.730 |
Why?
|
| Abdominal Neoplasms | 3 | 2019 | 249 | 0.710 |
Why?
|
| Endometrial Neoplasms | 5 | 2020 | 1382 | 0.680 |
Why?
|
| Ischium | 1 | 2019 | 11 | 0.670 |
Why?
|
| Radiographic Image Enhancement | 4 | 2018 | 410 | 0.660 |
Why?
|
| Fluorodeoxyglucose F18 | 7 | 2018 | 1259 | 0.600 |
Why?
|
| Radiology | 3 | 2022 | 428 | 0.480 |
Why?
|
| Positron-Emission Tomography | 6 | 2019 | 2198 | 0.440 |
Why?
|
| Neoplasm Staging | 14 | 2021 | 13989 | 0.440 |
Why?
|
| International Cooperation | 1 | 2014 | 326 | 0.430 |
Why?
|
| Magnetic Resonance Imaging | 12 | 2021 | 7929 | 0.410 |
Why?
|
| Genital Neoplasms, Female | 1 | 2018 | 790 | 0.370 |
Why?
|
| Rectal Neoplasms | 1 | 2019 | 1240 | 0.370 |
Why?
|
| Positron Emission Tomography Computed Tomography | 5 | 2019 | 879 | 0.360 |
Why?
|
| Diagnosis, Differential | 12 | 2021 | 4890 | 0.350 |
Why?
|
| Pelvis | 5 | 2020 | 384 | 0.340 |
Why?
|
| Liver Neoplasms | 4 | 2019 | 4805 | 0.310 |
Why?
|
| Skin Neoplasms | 2 | 2021 | 4888 | 0.300 |
Why?
|
| Melanoma | 2 | 2021 | 5591 | 0.290 |
Why?
|
| Pancreatic Neoplasms | 7 | 2022 | 5246 | 0.270 |
Why?
|
| Uterine Neoplasms | 3 | 2020 | 580 | 0.260 |
Why?
|
| Image Enhancement | 1 | 2009 | 555 | 0.260 |
Why?
|
| Liver | 3 | 2014 | 3123 | 0.260 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2017 | 2174 | 0.250 |
Why?
|
| Humans | 60 | 2023 | 271636 | 0.250 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2015 | 1707 | 0.240 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2021 | 2417 | 0.240 |
Why?
|
| Biomarkers, Tumor | 5 | 2019 | 10743 | 0.230 |
Why?
|
| Ligaments | 1 | 2004 | 42 | 0.230 |
Why?
|
| Thalidomide | 1 | 2007 | 595 | 0.230 |
Why?
|
| Tomography, Spiral Computed | 1 | 2004 | 128 | 0.220 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2004 | 110 | 0.220 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2019 | 1913 | 0.220 |
Why?
|
| Pancreatic Diseases | 1 | 2004 | 113 | 0.220 |
Why?
|
| Kidney Neoplasms | 3 | 2021 | 3150 | 0.210 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2007 | 1264 | 0.210 |
Why?
|
| Intestinal Neoplasms | 1 | 2004 | 201 | 0.210 |
Why?
|
| Peritoneum | 2 | 2020 | 150 | 0.200 |
Why?
|
| Liver Cirrhosis | 1 | 2009 | 1033 | 0.200 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2022 | 84 | 0.190 |
Why?
|
| Lymphoma | 4 | 2012 | 1514 | 0.190 |
Why?
|
| Female | 36 | 2023 | 148992 | 0.190 |
Why?
|
| Mucous Membrane | 1 | 2021 | 264 | 0.180 |
Why?
|
| Mixed Tumor, Mullerian | 1 | 2020 | 38 | 0.180 |
Why?
|
| Adrenocortical Adenoma | 1 | 2020 | 24 | 0.180 |
Why?
|
| Lymphocyte Depletion | 1 | 2021 | 311 | 0.170 |
Why?
|
| Pelvic Exenteration | 1 | 2020 | 112 | 0.170 |
Why?
|
| Neoplasms | 3 | 2023 | 15903 | 0.170 |
Why?
|
| Surgical Flaps | 3 | 2020 | 882 | 0.170 |
Why?
|
| Tuberous Sclerosis | 1 | 2021 | 144 | 0.170 |
Why?
|
| Anatomic Landmarks | 1 | 2019 | 51 | 0.160 |
Why?
|
| Adenoma | 1 | 2004 | 745 | 0.160 |
Why?
|
| Sensitivity and Specificity | 6 | 2020 | 5195 | 0.160 |
Why?
|
| Endometrium | 2 | 2019 | 469 | 0.160 |
Why?
|
| Liver Diseases | 1 | 2004 | 605 | 0.160 |
Why?
|
| Ovarian Neoplasms | 3 | 2019 | 4795 | 0.160 |
Why?
|
| Gastrointestinal Stromal Tumors | 2 | 2007 | 318 | 0.160 |
Why?
|
| Multimodal Imaging | 2 | 2019 | 553 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 3 | 2018 | 4070 | 0.150 |
Why?
|
| Carcinosarcoma | 1 | 2019 | 148 | 0.150 |
Why?
|
| Vaginal Neoplasms | 1 | 2018 | 155 | 0.140 |
Why?
|
| Hypercalcemia | 1 | 2017 | 145 | 0.140 |
Why?
|
| Middle Aged | 24 | 2021 | 90349 | 0.140 |
Why?
|
| Vulvar Neoplasms | 1 | 2018 | 236 | 0.130 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1013 | 0.130 |
Why?
|
| Stomach | 1 | 2019 | 405 | 0.130 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2018 | 341 | 0.130 |
Why?
|
| Statistics, Nonparametric | 3 | 2010 | 994 | 0.130 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2017 | 210 | 0.130 |
Why?
|
| Intestinal Diseases | 1 | 2016 | 126 | 0.130 |
Why?
|
| Lymphatic Metastasis | 1 | 2005 | 4967 | 0.130 |
Why?
|
| Ultrasonography | 2 | 2019 | 1935 | 0.130 |
Why?
|
| Cancer Vaccines | 1 | 2021 | 751 | 0.130 |
Why?
|
| Computed Tomography Angiography | 1 | 2017 | 247 | 0.120 |
Why?
|
| Aged, 80 and over | 13 | 2020 | 31032 | 0.120 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2020 | 532 | 0.120 |
Why?
|
| Anus Neoplasms | 1 | 2019 | 417 | 0.120 |
Why?
|
| Aged | 20 | 2021 | 73421 | 0.120 |
Why?
|
| Carcinoma, Small Cell | 1 | 2017 | 427 | 0.120 |
Why?
|
| Dendritic Cells | 1 | 2021 | 1110 | 0.120 |
Why?
|
| Radiography, Abdominal | 2 | 2006 | 124 | 0.120 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2021 | 1331 | 0.120 |
Why?
|
| Multidetector Computed Tomography | 1 | 2015 | 148 | 0.120 |
Why?
|
| Indoles | 2 | 2013 | 1034 | 0.120 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2013 | 1068 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2020 | 10354 | 0.110 |
Why?
|
| Hemorrhage | 1 | 2018 | 744 | 0.110 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2011 | 624 | 0.110 |
Why?
|
| Internationality | 1 | 2014 | 206 | 0.110 |
Why?
|
| Biopsy | 1 | 2021 | 3544 | 0.110 |
Why?
|
| Thigh | 1 | 2014 | 164 | 0.100 |
Why?
|
| Contrast Media | 5 | 2020 | 1510 | 0.100 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2018 | 741 | 0.100 |
Why?
|
| Pregnancy | 2 | 2023 | 8089 | 0.100 |
Why?
|
| Bridged-Ring Compounds | 1 | 2012 | 180 | 0.100 |
Why?
|
| Lactams, Macrocyclic | 1 | 2012 | 90 | 0.100 |
Why?
|
| Adult | 19 | 2021 | 81791 | 0.100 |
Why?
|
| Mutation | 3 | 2021 | 15913 | 0.100 |
Why?
|
| Benzoquinones | 1 | 2012 | 110 | 0.100 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 1838 | 0.090 |
Why?
|
| Hydroxamic Acids | 1 | 2013 | 455 | 0.090 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2012 | 190 | 0.090 |
Why?
|
| Vascular Neoplasms | 1 | 2011 | 113 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 2398 | 0.090 |
Why?
|
| Male | 23 | 2021 | 128836 | 0.090 |
Why?
|
| Pyrimidines | 3 | 2012 | 3663 | 0.090 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2011 | 261 | 0.080 |
Why?
|
| Colorectal Neoplasms | 1 | 2005 | 3697 | 0.080 |
Why?
|
| Sirolimus | 1 | 2013 | 833 | 0.080 |
Why?
|
| Gastrointestinal Tract | 1 | 2011 | 326 | 0.080 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 3934 | 0.080 |
Why?
|
| Radiologists | 2 | 2022 | 178 | 0.080 |
Why?
|
| Celiac Artery | 1 | 2008 | 43 | 0.080 |
Why?
|
| Mesenteric Arteries | 1 | 2008 | 66 | 0.080 |
Why?
|
| Janus Kinase 2 | 1 | 2012 | 754 | 0.070 |
Why?
|
| Radiopharmaceuticals | 3 | 2008 | 1338 | 0.070 |
Why?
|
| Cervix Uteri | 2 | 2019 | 252 | 0.070 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2012 | 629 | 0.070 |
Why?
|
| Neoplasms, Second Primary | 1 | 2015 | 1387 | 0.070 |
Why?
|
| Stomach Neoplasms | 1 | 2019 | 2317 | 0.070 |
Why?
|
| Disease Progression | 4 | 2018 | 6905 | 0.070 |
Why?
|
| Chondroblastoma | 1 | 2006 | 16 | 0.070 |
Why?
|
| Ilium | 1 | 2006 | 54 | 0.070 |
Why?
|
| Immunologic Factors | 1 | 2010 | 668 | 0.070 |
Why?
|
| Fibroma | 1 | 2006 | 87 | 0.060 |
Why?
|
| Interferon-alpha | 1 | 2010 | 961 | 0.060 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2007 | 333 | 0.060 |
Why?
|
| Sacrum | 1 | 2006 | 139 | 0.060 |
Why?
|
| Retrospective Studies | 10 | 2020 | 39731 | 0.060 |
Why?
|
| Liver Circulation | 1 | 2004 | 36 | 0.060 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2007 | 277 | 0.060 |
Why?
|
| Hodgkin Disease | 1 | 2013 | 1488 | 0.060 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2007 | 379 | 0.060 |
Why?
|
| Pancreas | 1 | 2008 | 745 | 0.060 |
Why?
|
| Adenocarcinoma | 2 | 2015 | 7971 | 0.060 |
Why?
|
| Salvage Therapy | 1 | 2012 | 2118 | 0.060 |
Why?
|
| Piperazines | 2 | 2007 | 2151 | 0.050 |
Why?
|
| Radiography | 2 | 2022 | 1991 | 0.050 |
Why?
|
| Duodenum | 1 | 2004 | 170 | 0.050 |
Why?
|
| Antineoplastic Agents | 4 | 2016 | 14653 | 0.050 |
Why?
|
| Bile Duct Neoplasms | 1 | 2007 | 498 | 0.050 |
Why?
|
| Treatment Outcome | 6 | 2021 | 33846 | 0.050 |
Why?
|
| Appendicitis | 1 | 2004 | 172 | 0.050 |
Why?
|
| Cholangiocarcinoma | 1 | 2007 | 501 | 0.050 |
Why?
|
| Portal Vein | 1 | 2004 | 364 | 0.050 |
Why?
|
| Appendiceal Neoplasms | 1 | 2004 | 251 | 0.050 |
Why?
|
| MART-1 Antigen | 1 | 2021 | 113 | 0.050 |
Why?
|
| Intestine, Small | 1 | 2004 | 526 | 0.050 |
Why?
|
| Pyrroles | 1 | 2004 | 592 | 0.050 |
Why?
|
| Genitalia, Female | 1 | 2020 | 85 | 0.040 |
Why?
|
| Leukemia, Myeloid | 1 | 2004 | 994 | 0.040 |
Why?
|
| Embolization, Therapeutic | 1 | 2004 | 605 | 0.040 |
Why?
|
| Radiation Injuries | 1 | 2006 | 1472 | 0.040 |
Why?
|
| Molecular Imaging | 1 | 2019 | 187 | 0.040 |
Why?
|
| Kidney | 2 | 2021 | 2265 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2004 | 4993 | 0.040 |
Why?
|
| Imatinib Mesylate | 2 | 2007 | 1690 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 4963 | 0.030 |
Why?
|
| Lung | 1 | 2008 | 3293 | 0.030 |
Why?
|
| Abdomen | 1 | 2018 | 348 | 0.030 |
Why?
|
| Benzamides | 2 | 2007 | 1882 | 0.030 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2017 | 192 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2007 | 13385 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 5113 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 5744 | 0.030 |
Why?
|
| Ovary | 1 | 2019 | 701 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2020 | 1550 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 1827 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2020 | 2035 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2007 | 4352 | 0.030 |
Why?
|
| Recurrence | 2 | 2012 | 4884 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 9042 | 0.030 |
Why?
|
| Interleukin-5 | 1 | 2013 | 69 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2004 | 658 | 0.030 |
Why?
|
| Observer Variation | 1 | 2015 | 720 | 0.030 |
Why?
|
| ROC Curve | 2 | 2007 | 1248 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 2006 | 2668 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 2532 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2019 | 1206 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 6208 | 0.020 |
Why?
|
| Time Factors | 2 | 2021 | 13116 | 0.020 |
Why?
|
| Everolimus | 1 | 2013 | 438 | 0.020 |
Why?
|
| Prevalence | 1 | 2019 | 3423 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 5102 | 0.020 |
Why?
|
| Prognosis | 2 | 2019 | 22525 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2014 | 731 | 0.020 |
Why?
|
| Risk Factors | 2 | 2018 | 18016 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2013 | 16606 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2013 | 1323 | 0.020 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2013 | 621 | 0.020 |
Why?
|
| Young Adult | 2 | 2021 | 22094 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 1618 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 2429 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 3538 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2019 | 9323 | 0.020 |
Why?
|
| Genomics | 1 | 2018 | 2830 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2013 | 1574 | 0.020 |
Why?
|
| Musculoskeletal System | 1 | 2006 | 37 | 0.020 |
Why?
|
| Thorax | 1 | 2008 | 230 | 0.020 |
Why?
|
| Viscera | 1 | 2006 | 92 | 0.020 |
Why?
|
| Triiodobenzoic Acids | 1 | 2006 | 69 | 0.020 |
Why?
|
| Adolescent | 2 | 2021 | 32609 | 0.020 |
Why?
|
| Propionates | 1 | 2004 | 79 | 0.020 |
Why?
|
| Hepatic Veins | 1 | 2004 | 59 | 0.010 |
Why?
|
| Absorptiometry, Photon | 1 | 2004 | 237 | 0.010 |
Why?
|
| Endpoint Determination | 1 | 2004 | 183 | 0.010 |
Why?
|
| Hepatic Artery | 1 | 2004 | 257 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2004 | 729 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2007 | 15254 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2012 | 9467 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2007 | 1842 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2006 | 1858 | 0.010 |
Why?
|
| Acute Disease | 1 | 2004 | 2510 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 4998 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2007 | 5328 | 0.010 |
Why?
|
| Survival Rate | 1 | 2010 | 12530 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2006 | 16943 | 0.010 |
Why?
|